ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
96.293
+1.963 (+2.081%)
As of 10:49AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close94.330
Open95.340
Bid95.330 x 100
Ask95.570 x 100
Day's Range94.150 - 96.470
52 Week Range51.330 - 153.990
Volume184,345
Avg. Volume998,053
Market Cap9.646B
Beta3.26
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Dicerna Pharmaceuticals Settles All Litigation with Alnylam
    Market Realist21 hours ago

    Dicerna Pharmaceuticals Settles All Litigation with Alnylam

    On April 20, Dicerna Pharmaceuticals (DRNA) announced that it had resolved all litigation with Alnylam Pharmaceuticals (ALNY). The settlement allows Dicerna to advance all its key and planned pipeline programs while simultaneously maintaining a strong balance sheet. Under the terms of the agreement, Alnylam will dismiss all claims of trade secret misappropriation and other related claims brought in Massachusetts against Dicerna Pharmaceuticals.

  • Motley Fool6 days ago

    Why Dicerna Rocketed Higher Today

    Investors are happy the biotech ended a lawsuit hanging over its head.

  • Dicerna to pay $27M to settle Alnylam trade secrets lawsuit
    American City Business Journals6 days ago

    Dicerna to pay $27M to settle Alnylam trade secrets lawsuit

    The Cambridge biotechs are both developing RNA interference drugs, which are designed to silence disease-causing genes.

  • Reuters6 days ago

    U.S. biotech companies Alnylam, Dicerna settle trade secrets case

    Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments. The settlement between the two biotech companies resolves a lawsuit that Alnylam filed against Dicerna in 2015. Under the agreement, Dicerna said it will pay Alnylam $2 million up-front plus 983,208 shares of its common stock.

  • Reuters6 days ago

    U.S. biotech companies Alnylam, Dicerna settle trade secrets case

    Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments. The settlement between the two biotech companies resolves a lawsuit that Alnylam filed against Dicerna in 2015. Under the agreement, Dicerna said it will pay Alnylam $2 million up-front plus 983,208 shares of its common stock.

  • Alnylam (ALNY) Reports Positive Data for RNAi Candidate
    Zacks9 days ago

    Alnylam (ALNY) Reports Positive Data for RNAi Candidate

    Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit13 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ALNY totaled $105 million.

  • Jakafi Continues to Be Strong Growth Driver for Incyte in 2018
    Market Realist15 days ago

    Jakafi Continues to Be Strong Growth Driver for Incyte in 2018

    Incyte has projected Jakafi’s GAAP (generally accepted accounting principles) and non-GAAP revenues for full-year 2018 to fall in the range of $1.35 billion to $1.4 billion. This revenue performance could be driven by an anticipated rise in demand for the drug in existing rare blood cancer indications of myelofibrosis (or MF) and polycythemia vera (or PV) as well as from potential new indications such as graft versus host disease (or GVHD) and essential-thrombocythemia (or ET). Jakafi has been granted orphan drug designation in MF, PV, ET, GVHD, and acute lymphoblastic leukemia (ALL) indications.

  • Why CASI Pharmaceuticals Stock Rose Last Week
    Market Realist15 days ago

    Why CASI Pharmaceuticals Stock Rose Last Week

    On Monday, April 2, 2018, CASI Pharmaceuticals (CASI) stock opened at $4.20. It grew ~68% over the week to close at $7.01 on April 6. Its 52-week low was $0.91 on June 20, 2017.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit16 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY

  • Forbes16 days ago

    A Sixth Sense For Biotech Has Made Joe Edelman A Hedge Fund Star

    Who's the world's best hedge fund manager? David Tepper? Stevie Cohen? Try Joe Edelman, a wannabe psychologist with a bead on biotech who has quietly built the best track record of the past two decades.

  • Benzinga20 days ago

    The Week Ahead In Biotech: PDUFA Dates, IPOs And More

    Here's a few must-watch biotech catalysts this week . Conferences Panamerican League of Associations for Rheumatology Congress – April 7-11 at Hotel Hilton, Buenos Aires, Argentina. The International Liver ...

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit20 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY

  • How Worried Should Alnylam and Ionis Really Be About Pfizer's New Data?
    Motley Fool23 days ago

    How Worried Should Alnylam and Ionis Really Be About Pfizer's New Data?

    A battle for transthyretin amyloidosis patients is brewing.

  • Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?
    Market Realist23 days ago

    Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?

    On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53. On March 29, Regeneron stock closed at $344.36, which represented a ~7.2% rise from its share price in the week ended March 23, 2017. On March 21, 2018, Regeneron Pharmaceuticals announced a collaboration agreement with Alnylam Pharmaceuticals (ALNY) for the identification of RNA interference therapeutics for the treatment of chronic liver disease NASH (non-alcoholic steatohepatitis) and other related diseases.

  • Market Exclusive23 days ago

    Here’s What Just Happened With Zosano Pharma Corporation And Pfizer Inc

    Zosano Pharma Corporation (NASDAQ:ZSAN) was a real end of the week mover in the biotechnology sector last week, with the company sliding close to 45% on the news that it is set to conduct an underwritten public offering. The public offering will see Zosano issue 10 million shares at an average price of five dollars […] The post Here’s What Just Happened With Zosano Pharma Corporation And Pfizer Inc appeared first on Market Exclusive.

  • Analysts’ Recommendations for United Therapeutics in March 2018
    Market Realist23 days ago

    Analysts’ Recommendations for United Therapeutics in March 2018

    A Look into the Performance of United Therapeutics in 2017

  • How Did United Therapeutics Perform in 4Q17 and Fiscal 2017?
    Market Realist24 days ago

    How Did United Therapeutics Perform in 4Q17 and Fiscal 2017?

    A Look into the Performance of United Therapeutics in 2017United Therapeutics’ revenue trends

  • Alnylam Falls on Pfizer's Rare Disease Drug Success
    Zacks24 days ago

    Alnylam Falls on Pfizer's Rare Disease Drug Success

    Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.

  • How Pfizer Sneaked Into Rare-Disease Market And Hit Alnylam, Ionis
    Investor's Business Daily24 days ago

    How Pfizer Sneaked Into Rare-Disease Market And Hit Alnylam, Ionis

    Alnylam and Ionis stocks fell Monday after Dow Jones component Pfizer announced strong results for a competing rare-disease drug.

  • Benzinga24 days ago

    With Alnylam Pharma Down More Than 15%, Analyst Says Buy The Dip

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) continued to decline after Pfizer Inc. (NYSE: PFE ) reported its transthyretin stabilizer Vyndaqel met primary Phase 3 endpoints Thursday. However, B Riley ...

  • Benzinga24 days ago

    Benzinga's Top Analyst Calls From April 2, 2018

    These headlines first appeared on Benzinga Pro . Stifel on Walmart Inc (NYSE: WMT ), Humana Inc (NYSE: HUM ) WSJ report: Expansion of an existing prescription drug plan partnership 'is most likely,' would ...

  • Why Alnylam Pharmaceuticals, Inc. Is Tanking Today
    Motley Fool24 days ago

    Why Alnylam Pharmaceuticals, Inc. Is Tanking Today

    Here's how a pretty good day for Pfizer ruined Alnylam's entire holiday weekend.

  • Why Pfizer's Big Win Is Bad News for Alnylam and Ionis
    Motley Fool24 days ago

    Why Pfizer's Big Win Is Bad News for Alnylam and Ionis

    Pfizer's latest clinical trial success could spell trouble for these two biotechs.

  • Pfizer's Rare Disease Candidate Meets Endpoint in Phase III
    Zacks24 days ago

    Pfizer's Rare Disease Candidate Meets Endpoint in Phase III

    Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.